Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Tarsus Pharmaceuticals, Inc.
Report date March 17, 2023 · Filed March 21, 2023
Section 16 reporting ended · disclosed 2023-03-21. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 3,191 |
Ending reported balance
After 2023-03-20 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2023-03-17 · Sale · Disposed 188 · Balance 3,389 F1: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. Row 2 · 2023-03-20 · Sale · Disposed 198 · Balance 3,191 F1: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. |
Filing footnotes · ownership attribution and instrument terms
F1: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 20, 2023 Filed Mar 21, 2023 23:06 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 198 | $12.61 | $2,496.78 |
DisclosureSEC source: 0001827564-23-000002 · wf-form4_167943994647637.xml · nonDerivative · entry 2 Holdbrook Mark J. · CIK 0001827564 · V.P., Clinical Affairs 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,191 F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| March 17, 2023 Filed Mar 21, 2023 23:06 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 188 | $13.28 | $2,496.64 |
DisclosureSEC source: 0001827564-23-000002 · wf-form4_167943994647637.xml · nonDerivative · entry 1 Holdbrook Mark J. · CIK 0001827564 · V.P., Clinical Affairs 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,389 F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| March 16, 2023 Filed Mar 17, 2023 22:22 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 187 | $13.43 | $2,511.41 |
DisclosureSEC source: 0001209191-23-019885 · doc4.xml · nonDerivative · entry 2 Holdbrook Mark J. · CIK 0001827564 · V.P., Clinical Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,577 F3 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| March 15, 2023 Filed Mar 17, 2023 22:22 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | Exercise / conversionRestricted Stock Units · Derivative | 2,653 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-019885 · doc4.xml · derivative · entry 3 Holdbrook Mark J. · CIK 0001827564 · V.P., Clinical Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,959 Underlying: Common Stock · 2,653 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Company's common stock. F5 · derivative.exercise_date: RSU granted on March 9, 2022, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2023, 2024, 2025, and 2026, subject to the Reporting Person's continuous service. F5 · derivative.expiration_date: RSU granted on March 9, 2022, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2023, 2024, 2025, and 2026, subject to the Reporting Person's continuous service. Read SEC document |
| March 15, 2023 Filed Mar 17, 2023 22:22 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | Exercise / conversionCommon Stock | 2,653 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-019885 · doc4.xml · nonDerivative · entry 1 Holdbrook Mark J. · CIK 0001827564 · V.P., Clinical Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,764 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). F1 · price: The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). F2 · balance_after: Includes 1,111 shares acquired under the Issuer's employee stock purchase plan on June 30, 2022. Read SEC document |
| March 09, 2022 Filed Mar 11, 2022 21:13 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | GrantRestricted Stock Units · Derivative | 10,612 | $0.00 | $0.00 |
DisclosureSEC source: 0001827564-22-000002 · wf-form4_164703319575280.xml · derivative · entry 2 Holdbrook Mark J. · CIK 0001827564 · V.P., Clinical Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,612 Underlying: Common Stock · 10,612 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company's common stock. F3 · derivative.exercise_date: 25% of the RSUs will vest on March 15th of each of 2023, 2024, 2025, and 2026, subject to the Reporting Person's continuous service. F3 · derivative.expiration_date: 25% of the RSUs will vest on March 15th of each of 2023, 2024, 2025, and 2026, subject to the Reporting Person's continuous service. Read SEC document |
| March 09, 2022 Filed Mar 11, 2022 21:13 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | GrantStock Option (right to buy) · Derivative | 36,173 | $0.00 Strike: $19.59 | $0.00 |
DisclosureSEC source: 0001827564-22-000002 · wf-form4_164703319575280.xml · derivative · entry 1 Holdbrook Mark J. · CIK 0001827564 · V.P., Clinical Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,173 Underlying: Common Stock · 36,173 shares Expires 2032-03-08 F1 · derivative.exercise_date: 25% of the option shares shall vest on March 9, 2023, and 1/48th of the option shares shall vest each month thereafter for a period of 3 years subject to the Reporting Person's continuous service. Read SEC document |
| March 02, 2021 Filed Mar 5, 2021 01:14 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | GrantStock Option (right to buy) · Derivative | 14,300 | $0.00 Strike: $34.72 | $0.00 |
DisclosureSEC source: 0001209191-21-018041 · doc4.xml · derivative · entry 1 Holdbrook Mark J. · CIK 0001827564 · V.P., Clinical Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,300 Underlying: Common Stock · 14,300 shares Expires 2031-03-02 F1 · derivative.exercise_date: Option granted under the Tarsus Pharmaceuticals, Inc. 2020 Equity Incentive Plan. 25% of the option shares shall vest and become exercisable on March 2, 2022, and 1/48th of the option shares shall vest and become exercisable each month thereafter for a period of 3 years. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.